An Advocate General in the Court of Justice of the European Union (CJEU), Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates (SPCs) should be interpreted concerning medicinal products made with a combination of active ingredients.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CJEU, SPCs, combination drugs, Actavis, Boehringer Ingleheim, supplementary protection certificates